NCT02729467View on ClinicalTrials.gov

A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Healthy
Interventions
DRUG

JNJ-53718678

JNJ-53718678 will be applied twice at doses of 250 mg (in Panel 1, Day 1 and Day 9) and 3 times at 500 mg (Panel 2, Day 1, 4 and 9).

DRUG

Itraconazole

Participants will receive itraconazole 200 mg (2 capsules of 100 mg) from Day 4-11.

DRUG

Rifampicin

Participants will receive 600 mg rifampicin (2 capsules of 300 mg) from Day 4-11.

Trial Locations (1)

Unknown

Overland Park

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02729467 - A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults | Biotech Hunter | Biotech Hunter